LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 23, Issue 5, 2003, Pages 853-858

  Lee, Sung Joon ^a,d   Campos, Hannia ^a   Moye, Lemuel A ^c   Sacks, Frank M ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apolipoprotein B; Apolipoprotein CIII; Apolipoprotein E; Coronary heart disease; Lipoproteins

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; CHOLESTEROL; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CASE CONTROL STUDY; CONTROLLED STUDY; CORONARY RISK; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; HEART INFARCTION; HUMAN; IMMUNOAFFINITY CHROMATOGRAPHY; ISCHEMIC HEART DISEASE; LIPOPROTEIN METABOLISM; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RECURRENT DISEASE; RISK FACTOR; ULTRACENTRIFUGATION;

APOLIPOPROTEIN C-III; APOLIPOPROTEINS C; CASE-CONTROL STUDIES; CHOLESTEROL; COMORBIDITY; CORONARY DISEASE; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PRAVASTATIN; PROSPECTIVE STUDIES; RECURRENCE; RISK; RISK FACTORS; TRIGLYCERIDES;

EID: 0038222533     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000066131.01313.EB     Document Type: Article

References (36)

1. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16: 434-444.
2. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Mortality from coronary heart disease and stroke in relation to degree of glycaemia: the Whitehall study. BMJ. 1983;287:867-870.
3. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham study. JAMA. 1979;241:2035-2038.
4. Seeman T, Mendes de Leon C, Berkman L, Ostfeld A. Risk factors for coronary heart disease among older men and women: a prospective study of community-dwelling elderly. Am J Epidemiol. 1993;138:1037-1049.
5. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, Holman RR. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ. 1998;316:823-828.
6. Fontbonne A, Eschwege E, Cambien F, Richard JL, Ducimetiere P, Thibult N, Warnet JM, Claude JR, Rosselin GE. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes: results from the 11-year follow-up of the Paris Prospective Study. Diabetologia. 1989;32:300-304.
7. Taskinen MR, Packard CJ, Shepherd J. Effect of insulin therapy on metabolic fate of apolipoprotein B-containing lipoproteins in NIDDM. Diabetes. 1990;39:1017-1027.
8. Malmstrom R, Packard CJ, Caslake M, Bedford D, Stewart P, YkiJarvinen H, Shepherd J, Taskinen MR. Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM. Diabetologia. 1997; 40:454-462.
9. Steiner G, Lewis GF. Hyperinsulinemia and triglyceride-rich lipoproteins. Diabetes. 1996;45(suppl 3):S24-S26.
10. Taskinen MR. Lipoprotein lipase in diabetes. Diabetes Metab Rev. 1987; 3:551-570.
11. Gustafson A, Alaupovic P, Furman RH. Studies of the composition and structure of serum lipoproteins: separation and characterization of phospholipid-protein residues obtained by partial delipidization of very low density lipoproteins of human serum. Biochemistry. 1966;5:632-640.
12. Alaupovic P, Bard JM, Tavella M, Shafer D. Identification of apoBcontaining lipoprotein families in NIDDM. Diabetes. 1992;41(suppl 2):18-25.
13. Alaupovic P. Significance of structure, function, and classification of plasma lipoprotein families. Methods Enzymol. 1996;263:32-60.
14. Ginsberg HN, Le NA, Goldberg IJ, Gibson JC, Rubinstein A, WangIverson P, Norum R, Brown WV. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI: evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest. 1986;78:1287-1295.
15. Ebara T, Ramakrishnan R, Steiner G, Shachter NS. Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice: apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E. J Clin Invest. 1997;99:2672-2681.
16. Sehayek E, Eisenberg S. Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway. J Biol Chem. 1991;266:18259-18267.
17. Sacks FM, Alaupovic P, Moye LA, Cole TG, Sussex B, Stampfer MJ, Pfeffer MA, Braunwald E. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation. 2000;102:1886-1892.
18. Gervaise N, Garrigue MA, Lasfargues G, Lecomte P. Triglycerides, apo C3, and Lp B. C3 and cardiovascular risk in type II diabetes. Diabetologia. 2000;43:703-708.
19. Chivot L, Mainard F, Bigot E, Bard JM, Auget JL, Madec Y, Fruchart JC. Logistic discriminant analysis of lipids and apolipoproteins in a population of coronary bypass patients and the significance of apolipoproteins C-III and E. Atherosclerosis. 1990;82:205-211.
20. Alaupovic P, Mack WJ, Knight-Gibson C, Hodis HN. The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial. Arterioscler Thromb Vasc Biol. 1997;17:715-722.
21. Weisgraber KH, Innerarity TL, Harder KJ, Mahley RW, Milne RW, Marcel YL, Sparrow JT. The receptor-binding domain of human apolipoprotein E: monoclonal antibody inhibition of binding. J Biol Chem. 1983;258:12348-12354.
22. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001-1009.
23. Campos H, Perlov D, Khoo C, Sacks FM. Distinct patterns of lipoproteins with apoB defined by presence of apoE or apoC-III in hypercholesterolemia and hypertriglyceridemia. J Lipid Res. 2001;42:1239-1249.
24. Khoo C, Judge H, Sacks FM. Effects of estrogenic oral contraceptives on the lipoprotein B particle system defined by apolipoproteins E and C-III content. J Lipid Res. 1999;40:202-212.
25. Lee SJ, Moye LA, Campos H, Williams GH, Sacks FM. Hypertriglyceridemia but not diabetes status is associated with VLDL containing apolipoprotein CIII in patients with coronary heart disease. Atherosclerosis. In press.
26. Pietzsch J, Subat S, Nitzsche S, Leonhardt W, Schentke KU, Hanefeld M. Very fast ultracentrifugation of serum lipoproteins: influence on lipoprotein separation and composition. Biochim Biophys Acta. 1995; 1254:77-88.
27. Leonhardt W, Pietzsch J, Nitzsche S. Very-fast ultracentrifugation of human plasma lipoproteins: influence of the centrifugal field on lipoprotein composition. Clin Chim Acta. 1994;224:21-32.
28. Lindgren FT, Silvers A, Jutaglr R, Layshot L, Bradley DD. A comparison of simplified methods for lipoprotein quantification using the analytic ultracentrifuge as a standard. Lipids. 1977;12:278-282.
29. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
30. Goldberg RB, Mellies MJ, Sacks FM, Moye LA, Howard BV, Howard WJ, Davis BR, Cole TG, Pfeffer MA. Braunwald E. Cardiovascular events and their reduction with pravastatin in diabetic and glucoseintolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol and Recurrent Events (CARE) trial. Circulation. 1998;98:2513-2519.
31. Campos H, Moye LA, Glasser SP, Stampfer MJ, Sacks FM. Low-density lipoprotein size, pravastatin treatment, and coronary events. JAMA. 2001; 286:1468-1474.
32. Havel RJ. Role of triglyceride-rich lipoproteins in progression of atherosclerosis. Circulation. 1990;81:694-696.
33. Krauss RM. Atherogenicity of triglyceride-rich lipoproteins. Am J Cardiol. 1998;81:13B-17B.
34. Krauss RM, Lindgren FT, Williams PT, Kelsey SF, Brensike J, Vranizan K, Detre KM, Levy RI. Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolaemic men. Lancet. 1987; 2:62-66.
35. Hodis HN, Mack WJ, Dunn M, Liu C, Selzer RH, Krauss RM. Intermediate-density lipoproteins and progression of carotid arterial wall intima-media thickness. Circulation. 1997;95:2022-2026.
36. Tomiyasu K, Walsh BW, Ikewaki K, Judge H, Sacks FM. Differential metabolism of human VLDL according to content of ApoE and ApoC-III. Arterioscler Thromb Vasc Biol. 2001;21:1494-1500.